Get access

The pridopidine paradox in Huntington's disease

Authors

  • Ralf Reilmann MD, PhD

    Corresponding author
    1. Huntington Center, Department of Neurology, University Clinic Muenster (UKM), Westfaelische Wilhelms University of Muenster, Muenster, Germany
    • Correspondence to: Dr. Ralf Reilmann, Chair Huntington Center, Dept. of Neurology, University Clinic Muenster (UKM), University of Muenster, Albert Schweitzer Campus 1 - Building A1, 48149 Muenster, Germany; r.reilmann@uni-muenster.de

    Search for more papers by this author

  • Relevant conflicts of interest/financial disclosures: Dr. Reilmann provided consulting services, advisory board functions, clinical trial services, quantitative motor analyses, and/or lectures for Novartis, Teva, Siena Bitoech, Neurosearch Inc., Medivation/Pfizer, Lundbeck, Ipsen, Wyeth, ISIS Pharma, Link Medicine, Prana Biotechnology, the Cure Huntington's Disease Initiative Foundation, MEDA, Temmler Pharma, and AOP Orphan Pharmaceuticals AG. He serves on the Advisory Board of the “Jacques and Gloria Gossweiler Foundation” and has several responsibilities in the European Huntington's Disease Network (member of the “Executive Committee” and the “Clinical Trials Task Force”, Lead Facilitator of the Neuroprotective Therapy and Motor Phenotype Working Groups) and serves as Global Coordinating Principle Investigator of clinical trials. Dr. Reilmann received grant support from the High-Q-Foundation, the Cure Huntington's Disease Initiative Foundation (CHDI), the Deutsche Forschungsgemeinschaft (DFG), the European Union (EU-FP7 program) and the European Huntington's Disease Network (EHDN).

  • Full financial disclosures and author roles may be found in the online version of this article.

Ancillary